8-K: Neuphoria Secures Nasdaq Extension for Annual Meeting

Neuphoria Therapeutics Inc. received a 180-day extension from Nasdaq to regain compliance with listing rules by holding its annual general meeting by December 29, 2025.

Summary

• Neuphoria Therapeutics Inc. (the Company) previously received a deficiency notification from Nasdaq on July 18, 2025, for failing to hold its annual general meeting of stockholders within twelve months of the fiscal year ended June 30, 2024, violating Nasdaq Listing Rule 5620(a).
• The Company submitted a plan to Nasdaq to regain compliance.
• On September 10, 2025, Nasdaq accepted the Company's plan and granted an extension of 180 calendar days, until December 29, 2025, to regain compliance.
• The Company intends to file its annual report on Form 10-K on or before September 29, 2025.
• The Company plans to timely file a proxy statement and notice of shareholder meeting and hold the annual shareholder meeting within the extended compliance period.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the initial failure to comply with a basic listing rule, indicating a governance lapse. However, the acceptance of the company's plan and the granting of an extension by Nasdaq provide a clear path to remediation, preventing a more severe negative outlook.

Positives

• Nasdaq accepted the Company's plan to regain compliance, providing a clear path forward.
• The Company was granted a 180-day extension, until December 29, 2025, to rectify the listing deficiency, mitigating immediate delisting concerns.

Negatives

• The Company failed to hold its annual general meeting of stockholders within the required timeframe, leading to a Nasdaq deficiency notice.
• The initial non-compliance with Nasdaq Listing Rule 5620(a) indicates a lapse in corporate governance and operational oversight.

Risks

• Inability to maintain the listing of its securities on Nasdaq.
• General risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission.

Future Outlook

The Company intends to file its annual report on Form 10-K by September 29, 2025, and subsequently file a proxy statement and notice for its 2025 annual general shareholder meeting, which it plans to hold by December 29, 2025, to regain Nasdaq compliance.

Management Comments

• We intend to file our annual report on Form 10-K on or before September 29, 2025.
• We intend to timely file a proxy statement and notice of shareholder meeting related to our 2025 annual general shareholder meeting.
• We intend to hold such annual shareholder meeting within the Compliance Period (by December 29, 2025).

Industry Context

Maintaining compliance with exchange listing rules, such as holding annual shareholder meetings, is a fundamental requirement for publicly traded companies. Failure to do so can lead to delisting, impacting investor confidence and access to capital markets. Nasdaq's decision to grant an extension is a common practice for companies that present a viable plan to rectify deficiencies.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the delay in the annual meeting, which is a key forum for corporate accountability and engagement. The risk of delisting, though mitigated by the extension, could impact share liquidity and value.
• Regulatory Authorities (Nasdaq, SEC): The company is under scrutiny to fulfill its compliance obligations within the extended timeframe.

Next Steps

• File annual report on Form 10-K on or before September 29, 2025.
• Timely file a proxy statement and notice of shareholder meeting for the 2025 annual general shareholder meeting.
• Hold the annual shareholder meeting within the Compliance Period, by December 29, 2025.

Key Dates

Recommendation

While the company received an extension from Nasdaq, averting an immediate delisting threat, the underlying issue of failing to hold an annual meeting signals a lapse in corporate governance. Investors should hold, but monitor closely for the timely execution of the company's plan to file its 10-K and hold the annual meeting by the December 29, 2025 deadline. Failure to meet these commitments could lead to further compliance issues and negatively impact the stock.

Keywords

Nasdaq compliance, listing deficiency, annual meeting, SEC filing, corporate governance, Neuphoria Therapeutics, Form 8-K, extension